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AbstrACt
Introduction Burn care represents a healthcare and 
economic burden to patients internationally. Choice of 
the most clinically effective treatment strategies requires 
evidence which is best obtained through high- quality 
randomised controlled trials (RCT). The number of 
published RCTs of burn care is increasing. However, trial 
quality and reporting standards are unclear. This study will 
assess the risk of bias and adequacy of reporting in recent 
burn care RCTs using tools endorsed by the Cochrane 
Collaboration.
Methods and analysis A systematic literature review will 
be undertaken, assessing parallel group RCTs evaluating 
therapeutic interventions for patients with cutaneous 
burns. Literature searches will use Ovid Medline, Ovid 
Embase, Web of Science and the Cochrane Library. 
Separate searches for each database will include medical 
subject heading and free text terms including ‘burn’, 
‘scald’, ‘thermal injury’ and ‘RCT’. Two reviewers will 
independently assess each study for inclusion. Risk of bias 
(RoB) will be assessed with the revised tool (RoB 2) and 
reporting completeness with the CONsolidated Standards 
of Reporting Trials (CONSORT) 2010 guidelines. We will 
report a narrative synthesis of all studies, including domain 
specific, and overall risk of bias for the primary outcome of 
each trial. Inter- rater agreement for RoB 2 will be reported 
using Fleiss’s Kappa. For adherence to the CONSORT 
guidelines, we will generate a completeness of reporting 
index for the five domains.
Ethics and dissemination No ethics approval is required 
because published documents will be used. Findings of the 
study will be disseminated in a peer- reviewed journal and 
presented at conferences.
PrOsPErO registration number CRD42018111020.
IntrOduCtIOn
In 2009, Chalmers and colleagues estimated 
clinical research waste to be 85% of global 
investment.1 Wastage was attributed to meth-
odological flaws in randomised controlled 
trials (RCTs). Poor quality RCTs may result in 
misleading conclusions increasing research 
waste.2–4 Numbers of RCTs in burn care 
research are increasing, as new technologies 
are regularly introduced.5–9 However, trial 
quality and adherence to reporting stan-
dards are uncertain.10–13 Previous studies 
are limited by their lack of comprehensive-
ness and methods of quality assessment.14–16 
Quality assessment of RCTs involves evalu-
ating internal and external validity. External 
validity assesses whether study results can be 
generalised to other populations.17 Internal 
validity, or risk of bias (RoB), is the extent 
to which the study design is free from bias; 
a systematic error that leads to a deviation of 
results from the truth.18 Transparent reporting 
is necessary to allow a clear assessment of the 
trial design and conduct as recommended by 
the Cochrane Collaboration.19 20
Using an objective method to assess RoB 
and reporting completeness has become 
increasingly common and considered good 
practice.18 21 For assessment of RoB, many 
tools are available, including overall scores 
and checklists.22 23 The Cochrane collabora-
tion endorse a different type of tool based 
on individual domains.18 RoB domains are 
assessed separately, with the overall RoB 
formed relating to the highest domain score. 
Accumulating evidence shows that this is the 
best tool for assessing the RoB of RCTs.24–26 A 
revised version of the tool (RoB 2) has been 
developed which now examines single trial 
outcomes, includes ‘signalling questions’ to 
aid decision- making and a method to allow 
strengths and limitations of this study
 ► This systematic review will be the first to assess 
both the internal validity of burn care randomised 
controlled trials using the Risk of Bias 2 (RoB 2) 
tool and adherence to CONsolidated Standards of 
Reporting Trials 2010 reporting guidelines.
 ► The inter- rater reliability of RoB 2 will be assessed 
using six reviewers from different research back-
grounds to simulate real- world conditions.
 ► The systematic review will be limited to 5 years and 
to articles published in English.
 ► Assessments of external validity will not be 
performed.
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box 1 Ovid Medline search strategy
Ovid Medline search strategy
1. Burns/(MESH) exp
2. Burn*.tw
3. Scald*.tw
4. Thermal* adj injur*.mp
5. or/1–4
6. Heartburn.mp
7. Burnout.mp
8. (Burn* adj out).mp
9. Burning.mp
10. Burnetii.mp
11. Burnish*.mp
12. Burnet*.mp
13. 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12
14. 5 NOT 13
15. Limit to RCT, clinical trial, English language, human, last five years
an overall RoB judgement.27 As yet, this tool has not been 
tested for inter- rater reliability. The Cochrane collab-
oration recommend ‘The CONsolidated Standards of 
Reporting Trials (CONSORT) statement’ to assess adher-
ence to reporting standards.28
The aim of this review is to assess the risk of bias and 
adherence to reporting standards using Cochrane- 
approved tools. It will also assess inter- rater reliability of 
the new RoB 2 tool.
MEthOds
This review will meet its aim with these objectives. It will:
 ► Determine the number of parallel- group, individually 
randomised trials assessing burn care interventions 
published over the last 5 years and retrieve included 
full- text articles.
 ► Assess the internal validity of the included RCTs using 
the revised Cochrane- endorsed RoB 2 tool.
 ► Assess the inter- rater reliability for the new RoB 2 tool.
 ► Assess the adherence of the included RCTs to 
CONSORT 2010 reporting guidelines.
Literature review search strategy
The systematic review will adhere to this prespecified 
protocol and the Preferred Reporting Items for System-
atic Reviews and Meta- Analyses (PRISMA) statement. This 
protocol will be aligned to the PRISMA- P statement.29–31 
It has been registered with the PROSPERO international 
prospective register of systematic reviews. We will report 
any amendments to the protocol that occur while under-
taking the study, within the final manuscript.
Study eligibility
Types of studies
Included studies must be full- text individually randomised 
parallel RCTs published in peer- reviewed journals limited 
to those allocating human subjects to an intervention or 
control group . We have planned to limit the search to 
the last 5- year period. We will not attempt to include all 
burn care RCTs, as would be undertaken in assessment of 
the effect of an intervention. Instead, we will investigate 
whether recent publications of burn care RCTs adhere 
to the CONSORT statement when reporting their find-
ings and whether the trials we include are at low risk 
of bias according to the revised Cochrane RoB 2. We 
will exclude RCT protocols, conference proceedings, 
abstracts, non- English language publications, interim 
analysis reports and studies not involving human subjects. 
Health economic evaluation reports of clinical trials will 
be considered if they contain enough information for 
assessing risk of bias (eg, clearly described methods for 
the trial conduct). We will also exclude trials that compare 
treatments within subjects as there is not yet a RoB 2 
tool designed for assessing such trials. Also, in burn care 
research, these are typically not cross- over trials as gener-
ally defined.32 33 Instead, they commonly use two wounds 
or two parts of the same wound. It is uncertain what the 
dependence between these might be or how treatments 
might ‘contaminate’ one another.
Types of participants
We will include studies evaluating two or more interven-
tions in patients of any age with cutaneous burns. Studies 
where the population consists of patients with combined 
burn and mechanical injuries will be excluded, as the 
data relating to burn patients alone are likely to be diffi-
cult to disaggregate.
Type of interventions
Interventions to treat cutaneous burns of any aetiology.
Types of outcome
Clinical or patient- reported outcomes. Laboratory studies 
will be excluded.
Identification of studies
A predefined search strategy previously designed by 
the authors in conjunction with experienced system-
atic reviewers to identify RCTs in the field of burn care 
will be used. Electronic searches of Ovid Medline, Ovid 
Embase, Web of Science and The Cochrane Library will 
be searched using medical subject heading and free- text 
terms including ‘burn’, ‘scald’ ‘thermal injury’ and ‘RCT’. 
To limit the search to RCTs, we will use terms derived from 
published RCT search strategies on Medline and the BMJ 
best practice guideline.34 35 The thesaurus vocabulary of 
each database will be used to adapt the search terms. The 
search strategy for Ovid Medline is included in a previous 
publication and in Table 1.36
study selection process
Before screening abstracts and full- text papers, authors 
undertaking study selection, RoB 2 assessment and data 
extraction, will undergo training to ensure a comparable 
understanding of the purpose of the review and the 
eligibility criteria. The reference management software 
EndNote (Endnote X8 Clarivate Analytics) will be used 
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box 2 reasons for full- text exclusion
 ► Duplicate.
 ► Not published within time period.
 ► Population not consisting of burn patients alone.
 ► Not a parallel group RCT.
 ► Not in English.
 ► Non- human/animal study.
 ► No full text available.
 ► Laboratory- based study.
 ► Volunteer study.
 ► Oesophageal burns only.
 ► Ocular burns only.
 ► Anaesthetic/sedation technique only (pain management included).
 ► Smoke inhalation injuries without an associated cutaneous burn.
 ► Diagnostic test trial.
 ► Protocol only.
to compile all titles derived from the initial searches, with 
duplicates removed, for the review authors to screen titles 
and abstracts against the eligibility criteria. Screening 
of titles and abstracts will be completed by one reviewer 
(AY). Of these, 20% will be checked by another reviewer 
independently (DM). Any studies appearing to meet the 
inclusion criteria based on the abstract will be retrieved 
as full- text articles. Two reviewers will then read the full- 
text articles in their entirety to assess for eligibility, with 
decisions on inclusion and exclusion recorded (AY,DM). 
Reasons for exclusion will be ordered hierarchically from 
most to least important (box 2) and applied to each full- 
text paper. The most important reason for exclusion 
met by a paper will be recorded as the reason for exclu-
sion. Any disagreements will be discussed with senior 
researchers (JB, BR).
data extraction and analysis
All studies will be assessed by two reviewers inde-
pendently and then in duplicate (AY, DM), with disagree-
ments resolved by discussion until consensus is reached 
or by a senior reviewer (BR). Data will be extracted into 
a standardised data extraction Microsoft Excel spread-
sheet which will be specifically designed for this study. 
It will be adapted from the RoB 2 tool to include details 
for the CONSORT checklist by one of the coauthors 
(H- YC). Before starting the assessment, reviewers will 
undergo training with the spreadsheet. The reviewers 
will then independently pilot test each tool on five RCTs. 
If there are significant differences in the application of 
the tools in the pilot round, additional testing will be 
undertaken.37
Data extracted will include study details and research 
design. Study details will include author, publication year, 
number of sites and number of participants recruited 
per trial, design (full RCT, pilot study) and intervention 
tested. Risk of bias judgement will be reported for all trial 
primary outcomes at domain and overall level. Complete-
ness of reporting will be reported for all RCTs.
Assessment of risk of bias
Included studies will be objectively assessed for internal 
validity using RoB 2.38 The tool has five domains to 
assess bias arising from randomisation, deviations from 
intended interventions, missing outcome data, outcome 
measurement and in selection of the reported result. The 
assessment is specific to a single trial outcome. Catego-
ries of the overall risk of bias for the study outcome are 
low (risk of bias is low for all domains), some concerns 
(some concerns in at least one domain) and high (high 
risk of bias for at least one domain or some concerns for 
multiple domains).
Choice of outcome
Risk of bias will be assessed for the treatment effect 
for the primary outcome in each included trial. If the 
primary outcome is not reported explicitly, we will use 
the following decision rule to select the treatment effect 
to report: we will assess the treatment effect for the 
outcome used to calculate sample size and, if this too is 
not reported, assess the treatment effect for the outcome 
named in the title, then the first reported outcome in the 
results.37
Assessment of the inter-rater agreement of the RoB 2 tool
As RoB 2 is new, measuring agreement between reviewers 
will help assess whether the new guidance with signal-
ling questions has improved the reliability of the tool 
compared with the previous version.39–43 To evaluate the 
inter- rater agreement, six independent reviewers will 
assess the same 30 studies allocated in a balanced incom-
plete blocks design (please see Appendix A), ensuring 
that each study is rated 3 times, each assessor rates 15 
studies and all pairs of assessors rate 6 studies. Inter- rater 
agreement will be measured for each domain of bias 
and for the overall RoB judgement by calculating Fleiss’s 
Kappa scores.44 45 We will categorise agreement as poor 
(0.00), slight (0.01–0.20), fair (0.21–0.40), moderate 
(0.41–0.60), substantial (0.61–0.80) or almost perfect 
(0.81–1.00).26
AssEssMEnt Of rEPOrtIng COMPLEtEnEss
Completeness of reporting for each included RCT will 
be assessed using the latest revision of the CONSORT 
statement checklist.46 For assessing completeness of 
reporting, we will calculate a reporting index defined as 
the percentage of items reported in each of five domains 
(title/abstract, introduction, methods, results and discus-
sion), as has been done previously.47
Patient and public involvement
There was no patient or public involvement in designing 
the study or writing up the study protocol.
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